Literature DB >> 23036248

Pharmacotherapy for pulmonary hypertension.

Robin H Steinhorn1.   

Abstract

Pulmonary arterial hypertension is a serious disease with significant morbidity and mortality. Although it can occur idiopathically, it is more commonly associated with other cardiac or lung diseases. While most of the available therapies have been tested in adult populations and most therapies in children remain off-label, new reports and randomized trials are emerging that inform the treatment of pediatric populations. This review discusses currently available therapies for pediatric pulmonary hypertension, their biological rationales, and evidence for their clinical effectiveness.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23036248      PMCID： PMC3466474          DOI： 10.1016/j.pcl.2012.07.011

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN： 0031-3955            Impact factor:   3.278


  121 in total

1.  Iloprost as 'rescue' therapy for pulmonary hypertension of the neonate.

Authors:  Daniele De Luca; Enrico Zecca; Marco Piastra; Costantino Romagnoli
Journal:  Paediatr Anaesth       Date:  2007-04       Impact factor: 2.556

2.  Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure.

Authors: 
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

3.  Inhaled nitric oxide and bronchopulmonary dysplasia.

Authors:  Robin H Steinhorn; Philip W Shaul; Raye-Ann O deRegnier; Kathleen A Kennedy
Journal:  Pediatrics       Date:  2011-07       Impact factor: 7.124

4.  Inhalative iloprost - pharmacology and clinical application.

Authors:  Ralf Ewert; Christoph Schäper; Michael Halank; Sven Gläser; Christian F Opitz
Journal:  Expert Opin Pharmacother       Date:  2009-09       Impact factor: 3.889

5.  Medical therapy for pediatric pulmonary arterial hypertension.

Authors:  Cecile Tissot; David Dunbar Ivy; Maurice Beghetti
Journal:  J Pediatr       Date:  2010-07-24       Impact factor: 4.406

6.  Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study.

Authors:  F Eifinger; N Sreeram; K Mehler; C Huenseler; A Kribs; B Roth
Journal:  Klin Padiatr       Date:  2007-08-21       Impact factor: 1.349

7.  Can inhaled prostacyclin stimulate surfactant in ELBW infants?

Authors:  K Olmsted; O Oluola; A Parthiban; T Raghuveer
Journal:  J Perinatol       Date:  2007-11       Impact factor: 2.521

8.  Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension.

Authors:  Frederick E Barr; Rommel G Tirona; Mary B Taylor; Geraldine Rice; Judith Arnold; Gary Cunningham; Heidi A B Smith; Adam Campbell; Jeffrey A Canter; Karla G Christian; Davis C Drinkwater; Frank Scholl; Ann Kavanaugh-McHugh; Marshall L Summar
Journal:  J Thorac Cardiovasc Surg       Date:  2007-08       Impact factor: 5.209

9.  Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program.

Authors:  Maurice Beghetti; Marius M Hoeper; David G Kiely; Joern Carlsen; Barbara Schwierin; Eleanor S Segal; Marc Humbert
Journal:  Pediatr Res       Date:  2008-08       Impact factor: 3.756

10.  Iloprost in persistent pulmonary hypertension of the newborn.

Authors:  Michael Ehlen; Beatrix Wiebe
Journal:  Cardiol Young       Date:  2003-08       Impact factor: 1.093
View more
  7 in total

1.  Enhanced NO-dependent pulmonary vasodilation limits increased vasoconstrictor sensitivity in neonatal chronic hypoxia.

Authors:  Joshua R Sheak; Laura Weise-Cross; Ray J deKay; Benjimen R Walker; Nikki L Jernigan; Thomas C Resta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

Review 2.  Prenatal programming of pulmonary hypertension induced by chronic hypoxia or ductal ligation in sheep.

Authors:  Demosthenes G Papamatheakis; Madalitso Chundu; Arlin B Blood; Sean M Wilson
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

3.  Looking beyond PPHN: the unmet challenge of chronic progressive pulmonary hypertension in the newborn.

Authors:  Candice D Fike; Judy L Aschner
Journal:  Pulm Circ       Date:  2013-11-19       Impact factor: 3.017

Review 4.  Prostanoids and their analogues for the treatment of pulmonary hypertension in neonates.

Authors:  Binoy Shivanna; Sharada Gowda; Stephen E Welty; Keith J Barrington; Mohan Pammi
Journal:  Cochrane Database Syst Rev       Date:  2019-10-01

5.  Hydrocortisone normalizes phosphodiesterase-5 activity in pulmonary artery smooth muscle cells from lambs with persistent pulmonary hypertension of the newborn.

Authors:  Marta Perez; Stephen Wedgwood; Satyan Lakshminrusimha; Kathryn N Farrow; Robin H Steinhorn
Journal:  Pulm Circ       Date:  2014-03       Impact factor: 3.017

6.  Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants.

Authors:  Christoph P Hornik; Nikolas J Onufrak; P Brian Smith; Michael Cohen-Wolkowiez; Matthew M Laughon; Reese H Clark; Daniel Gonzalez
Journal:  Cardiol Young       Date:  2017-08-08       Impact factor: 1.023

7.  Age dependency of vasopressin pulmonary vasodilatory effect in rats.

Authors:  Masahiro Enomoto; Jingyi Pan; Yulia Shifrin; Jaques Belik
Journal:  Pediatr Res       Date:  2013-11-20       Impact factor: 3.756
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.